Skip to main content

Delcath Systems Value Stock - Dividend - Research Selection

Delcath systems

ISIN: US24661P5008 , WKN: A2AP0C

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Delcath Systems, Inc. (Delcath) is a pharmaceutical and medical device company specializing in oncology that focuses on developing medicines and initially causes cancer in the liver. Delcath focuses on the development and clinical study of the Delcath chemosuppressive system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the target organ. Once the organ is isolated, the Delcath chemosuppression system delivers doses of chemotherapeutic agents directly to the liver. The Delcath chemosuppression system includes a series of three catheter insertions, each of which is placed percutaneously by interventional radiology techniques. The procedure is minimally invasive and repeatable, allowing for multiple treatment cycles with chemotherapeutic drugs. On April 13, 2011, it received the Conformite Europeenne (CE) mark for the Delcath Hepatic CHEMOSAT Delivery System (CHEMOSAT System).

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)

2024-02-22
NEW YORK, Feb. 22, 2024 /PRNewswire/ -- Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the...

12 Health Care Stocks Moving In Monday's After-Market Session

2024-02-19
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2024-02-16
Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of three individuals whose employment commenced in January 2024.

Retail investors account for 52% of Delcath Systems, Inc.'s (NASDAQ:DCTH) ownership, while institutions account for 40%

2024-02-15
Key Insights Significant control over Delcath Systems by retail investors implies that the general public has more...

Delcath Systems Executives Announce Retirement Plans

2024-02-14
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Delcath Systems Inc at Lytham Partners Fall Investor Conference Transcript

2024-02-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Delcath Systems Inc Annual Shareholders Meeting Transcript

2024-02-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Q3 2023 Delcath Systems Inc Earnings Call Transcript

2024-02-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Delcath Systems Inc at Lytham Partners Spring Investor Conference (Virtual) Transcript

2024-02-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Q3 2022 Delcath Systems Inc Earnings Call Transcript

2024-02-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.